An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Equillium to Present at Two Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Equillium, a clinical-stage biotechnology company, announces participation in the Wells Fargo Healthcare Conference on September 7 and the H.C. Wainwright Annual Global Investment Conference on September 12. The company will provide insights into its clinical assets and upcoming milestones.
The Wells Fargo event will take place at Encore Boston Harbor at 1:20 PM PT, while the H.C. Wainwright event will be held at Lotte New York Palace Hotel at 12:00 PM PT. Webcast access will be available on Equillium's website.
Positive
None.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Wells Fargo Healthcare Conference and a corporate presentation at the H.C. Wainwright Annual Global Investment Conference.
Management will provide a high-level overview of the company, clinical assets, clinical programs and upcoming catalysts and milestones. Management will also be available for one-on-one meetings during both conferences.
Conference:
Wells Fargo Healthcare Conference
Location:
Encore Boston Harbor, Presentation Room 3
Date:
Wednesday, September 7
Time:
1:20 pm Pacific Time | 4:20 pm Eastern Time
Conference:
H.C. Wainwright Annual Global Investment Conference
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel immunomodulatory assets targeting immuno-inflammatory pathways. Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells, is currently in a Phase 3 study for patients with acute graft-versus-host disease (aGVHD) and is in a Phase 1b study for patients with lupus/lupus nephritis. EQ101, a first-in-class tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15, is Phase 2 ready and expected to begin enrolling patients in an alopecia areata study in the second half of 2022. EQ102, a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Phase 1 study anticipated to include normal healthy volunteers and celiac disease patients, in the second half of 2022.
